MIT’s tiny technologies go to Washington
Cancer nanomedicine was on display at the 2023 White House Demo Day.
Cancer nanomedicine was on display at the 2023 White House Demo Day.
MIT professor combines nanoscience and viruses to develop solutions in energy, environment, and medicine.
Researchers are working to advance the field of glycoscience, illuminating the essential role of carbohydrates for human health and disease.
MIT and MGH researchers design a local, gel-based drug-delivery platform that may provoke a system-wide immune response to metastatic tumors.
The wearable device, designed to monitor bladder and kidney health, could be adapted for earlier diagnosis of cancers deep within the body.
High schooler Dustin Liang estimated his blood cell counts by applying knowledge from an MITx course and talking to doctors.
Thirteen new graduate student fellows will pursue exciting new paths of knowledge and discovery.
MIT spinout Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new drug targets.
Brad Pentelute and his lab compel the anthrax delivery system to deliver antibody and peptide variants into cells to treat cancer.
The findings could help doctors identify cancer patients who would benefit the most from drugs called checkpoint blockade inhibitors.
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
Predictions from the OncoNPC model could enable doctors to choose targeted treatments for difficult-to-treat tumors.
In addition to turning on genes involved in cell defense, the STING protein also acts as an ion channel, allowing it to control a wide variety of immune responses.
The new device, which can be incorporated into a bra, could allow more frequent monitoring of patients at high risk for breast cancer.
MIT researchers find timing and dosage of DNA-damaging drugs are key to whether a cancer cell dies or enters senescence.